The World Health Organization (WHO) has approved two additional versions of the AstraZeneca/University of Oxford Covid-19 vaccine for emergency use. The vaccines in question are being produced by AstraZeneca-SKBio in South Korea and the Serum Institute of India. This approval allows the vaccines to be rolled out globally with the help of the COVAX facility.
According to reports by RIA news agency, India is likely to approve Russia’s Sputnik V vaccine to tackle Covid-19. The Russian vaccine candidate is currently being tested for safety and efficacy in small human trials being conducted in India. India’s Dr Reddy’s Laboratories and the Russian Direct Investment Fund (RDIF) have been collaborating to conduct these trials.
Novavax and SK Bioscience have expanded their collaboration and license agreement for 40 million doses of the former’s Covid-19 vaccine in South Korea. In addition, SK Bioscience has obtained a license to increase the production capacity and supply to the South Korean government.
According to the German biotech firm Leukocare, a pan-European consortium developing a Covid-19 vaccine is currently in discussion with big pharma to receive support for late-stage development of the jab and also to ramp up manufacturing. Leukocare has collaborated with Italy’s ReiThera and Belgium’s Univercells on an adenovirus vaccine candidate, which is similar to Covid-19 vaccines being developed by AstraZeneca/Oxford and Johnson & Johnson.